A meta-analysis of sham-controlled renal denervation trials published in the Journal of the American College of Cardiology found the catheter-based procedure was associated with statistically significant drops in ambulatory and office blood pressure measurements among hypertensive patients.

People who reported waking up in the middle of the night to use the bathroom were 40 percent more likely to have hypertension, according to a study presented March 30 at the Japanese Circulation Society’s annual scientific meeting.

The American Diabetes Association (ADA) issued updates to its 2019 Standards of Medical Care in Diabetes on March 27 in light of recent evidence surrounding icosapent ethyl and dapagliflozin.

More than 85 percent of African-American men and women are likely to develop hypertension in their lifetimes based on the new cutoff for high blood pressure established in the 2017 U.S. guidelines, researchers reported March 27 in JAMA Cardiology.

Nearly 60 percent of patients who met guideline-based criteria for statin therapy but weren’t taking the cholesterol-lowering drugs said they were never offered one, according to a study published March 27 in the Journal of the American Heart Association.

In the largest-ever randomized trial of antihypertensive drug treatment in sub-Saharan Africa, two medication combinations including the long-acting calcium channel blocker amlodipine outperformed a third two-drug combination featuring a diuretic and an angiotensin-converting-enzyme (ACE) inhibitor.

Hypertensive patients from the RADIANCE-HTN SOLO trial who received renal denervation sustained a lower blood pressure through six months compared to participants randomized to a sham procedure, despite being placed on fewer antihypertensive medications during follow-up.

NEW ORLEANS — A new analysis considering not only a patient's first cardiovascular event—but the second, third and beyond—paints the REDUCE-IT trial in an even more positive light.